Policies: A Commitment to Patients
Bristol-Myers Squibb is committed – through a diverse group of commercial and non-commercial programs – to providing universal access to all our medicines. This effort relates directly to our company’s objective to address unmet medical needs in a number of specific diseases and therapeutic areas, including those of special concern in parts of the developing world. With others, we understand we have an important role to play, first and foremost by developing treatments that address unmet medical needs, and also by working with payers, physicians, patients and civil society to enhance access.
- Company Policies: Bristol-Myers Squibb has developed specific policies to guide many of these efforts. We have policy statements, for example, that frame an HIV Global ACCESS Program operating primarily in sub-Saharan Africa. We also have policies outlining our responsibilities in the area of Bioethics, and the Disclosure of Clinical Trial Information. Outside the U.S., especially in the developing world, we deploy various programs and approaches to meet patient needs. We also have an Early/Expanded Access Program and a Named Patient Program for facilitating emergency access to certain investigational drugs. A Direct Import Program, meanwhile, helps patients gain access to certain existing products that might otherwise be unavailable.
- Governance: In addition to overseeing specific policies, Bristol-Myers Squibb’s Board of Directors has a Science and Technology Committee that focuses on various science/disease issues and opportunities. In philanthropy governance, CEO Lamberto Andreotti and Executive Vice President and Chief Scientific Officer Elliott Sigal, M.D., Ph.D., serve on the Bristol-Myers Squibb Foundation’s Board of Directors.
- The company also has a Worldwide Market Access Council and a Global Medical Council that advise senior leadership on access-related policy initiatives.